EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency

Yiming Lin, Zhenzhu Zheng, Weihua Lin, Weilin Peng iD

Molecular Genetics & Genomic Medicine · 2024

DOI: 10.1002/mgg3.70003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2024. Verfasst von Yiming Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Quanzhou Maternity and Children's Hospital, Quanzhou, Fujian, China. Hauptthemen laut MEDLINE: Carnitine, Solute Carrier Family 22 Member 5, High-Throughput Nucleotide Sequencing, Hyperammonemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujian Provincial Society of Laboratory Medicine and National (Fujian) Genetic Testing Technology Application Demonstration Center, Quanzhou City Science and Technology Program of China, Joint Innovation Project of Huaqiao University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Newborn screening (NBS) for primary carnitine deficiency (PCD) has poor performance. This study aimed to evaluate the feasibility of incorporating next‐generation sequencing (NGS) as a second‐tier PCD test.

Methods

Between March and December 2020, 60,070 newborns were screened for inherited metabolic disorders. Newborns with free carnitine (C0) levels below 8.5 μmol/L were selected for second‐tier genetic testing.

Results

In total, 130 (0.22%) newborns with low C0 levels underwent second‐tier genetic testing, 87 (66.92%) had positive genetic testing results, and 30 (23.08%) carried pathogenic variants of the SLC22A5 gene. Six newborns were diagnosed with PCD. The incidence of PCD was approximately 1 in 1:10,012 newborns. The PPV reached 20% after combining with second‐tier NGS. Of the eight variants identified in patients with PCD, the three most common variants were c.760C>T (p.Arg254*), c.51C>G (p.Phe17Leu), and c.1400C>G (p.Ser467Cys). The C0 levels of patients with PCD were significantly lower than those of PCD carriers ( p = 0.0026) and PCD‐negative individuals ( p = 0.0005).

Conclusions

Our results showed that the PPV reached 20% after combining with second‐tier NGS. The MS/MS‐based NBS and second‐tier NGS combination can effectively reduce the false‐positive rate and detect PCD in patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarnitineSolute Carrier Family 22 Member 5High-Throughput Nucleotide SequencingHyperammonemiaGenetic TestingHumansInfant, NewbornMaleFemaleCardiomyopathiesNeonatal ScreeningMuscular DiseasesMutation

Stichwörter der Autor:innen

free carnitinenewborn screeningnext‐generation sequencingprimary carnitine deficiencysecond‐tier screening

Substanzen

CarnitineSolute Carrier Family 22 Member 5SLC22A5 protein, human

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Quanzhou Maternity and Children's Hospital, Quanzhou, Fujian, China.
  • Neonatal Disease Screening Center, Quanzhou Maternity and Children's Hospital, Quanzhou, Fujian, China.

ORCID-Profile: Weilin Peng

Förderung

  • Fujian Provincial Society of Laboratory Medicine and National (Fujian) Genetic Testing Technology Application Demonstration Center
  • Quanzhou City Science and Technology Program of China
  • Joint Innovation Project of Huaqiao University

Zitieren

APA

Lin, Y., Zheng, Z., Lin, W., & Peng, W. (2024). Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.70003

Vancouver

Lin Y, Zheng Z, Lin W, Peng W. Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency. Molecular Genetics & Genomic Medicine. 2024. doi:10.1002/mgg3.70003

BibTeX
@article{Lin2024,
  author = {Lin, Yiming and Zheng, Zhenzhu and Lin, Weihua and Peng, Weilin},
  title = {Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency},
  journal = {Molecular Genetics & Genomic Medicine},
  year = {2024},
  doi = {10.1002/mgg3.70003}
}
Kostenlos starten →